Furthermore, we demonstrated that the combination of elesclomol and SIRT2 inhibitor AGK2 is a promising therapeutic strategy, and tackles the research bottleneck of cuproptosis on tumor therapy. The gene discussed is SIRT2; the disease is neoplasm.